Lonnie Moulder

Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA.

The Fox Chase Cancer Center owns and operates hospitals. It is an independent, non-profit institution that is engaged in cancer treatment, research and prevention services. The firm's staff provides consultations and treatment recommendations for different types of adult cancer. The company was founded in 1904 and is headquartered in Philadelphia, PA.

Part of Eisai Co., Ltd., Eisai Corp. of North America is a pharmaceutical company that manufactures pharmaceutical products. The private company is based in Woodcliff Lake, NJ.

MGI PHARMA Biologics, Inc. develops and markets pharmaceutical and medical therapies. The company's products amolimogene and ZYC300 represent a breakthrough in the activition of cytotoxic cells. The company was founded in 1979 and is located in Lexington, MA

Temple University Hospital, Inc. owns and operates a healthcare centre. The company provides pulmonology, cardiology, gastroenterology, hematology, nephrology, oncology, neurology, ophthalmology, otorhinolaryngology, and bone marrow transplantation services. Additionally, it offers heart, lung, kidney, and trauma surgery; maxillofacial surgery; psychiatry; radiation oncology; and diagnostic imaging services. The company also provides treatment of infectious diseases and diabetes. The company was founded in 1992 and is headquartered in Philadelphia, PA.

Navrogen, Inc. is a biotechnology company, which engages in the discovery and development of tumor produced HIO-factors that are associated with cancer prognosis and therapeutic response of immune-mediated anti-cancer therapies. The company was founded by Luigi Grasso and Nicholas C. Nicolaides in 2017 and is headquartered in Philadelphia, PA.

Dianthus Therapeutics OpCo, Inc. provides heath care services. The company was founded by Jonathan Violin and is headquartered in Waltham, MA.

Aegle Therapeutics Corp. is a biotechnology company, which isolates extracellular vesicles including exosomes (“EVs”) secreted by allogeneic bone marrow derived mesenchymal stem cells to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric connective tissue disorder. Its EV therapy has the potential to demonstrate a safer, lower cost means of harnessing the regenerative healing power of stem cells without using the cells. The company was founded by Evangelos V. Badiavas, and Robert F. Williamson III in 2013 and is headquartered in Miami, FL.

Tamurobio, Inc. provides biotechnology services. The company was founded in 2019 and is headquartered in Wayne, PA.

Tellus BioVentures LLC (Tellus BioVentures) is a venture capital firm founded in 2019 by Leon O. Moulder. The firm is headquartered in Miromar Lakes, Florida.

Interius BioTherapeutics, Inc. is a biopharmaceutical company that targets cancer. The company was founded by Saar Gill and is headquartered in Philadelphia, PA.

viTToria Biotherapeutics, Inc. is a gene-edited cell therapeutics company based in Philadelphia, PA. The company is developing novel CAR-T cell therapies using their proprietary Senza5 platform, which maximizes stemness, durability, and target cell cytotoxicity. The technology is exclusively licensed from the University of Pennsylvania and has pipeline applications in oncology and autoimmune diseases. The company was founded by Bruce A. Peacock and Nicholas Siciliano, with Nicholas Siciliano serving as CEO since incorporation.

Zenas Pharma, Inc. is an American pharmaceutical company that is focused on developing a portfolio of first- and autoimmune therapeutics to address areas of high unmet medical need. The company is located in the US. The company's lead product candidate, obexelimab (zb012), is a novel bifunctional antibody with first-in-class potential that inhibits B-cell lineages that express CD19.

Praeventix, Inc. is a biotechnology company founded by Dr. Douglas Pippin based on discoveries researched by Dr. Pippin and at Temple University. The company is based in Exton, PA, and was founded by Douglas Pippin. The company is initially focused on the development of pre-clinical candidate pra-523, a potential first-in-class neuromodulatory therapy for pruritus and other potential indications, including IBD. Praeventix is pursuing novel serotonergic therapeutics for inflammatory bowel disease (IBD) and cocaine use disorder (CUD). Douglas Pippin has been the CEO since incorporation.